Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5XMHB)

Drug Name

UC-781 Drug Info

Synonyms

Thiocarboxanilide; UC-040; UC-10; UC-82; Oxathiin carboxanilide analogs, Biosyn/CONRAD; UC analogs, Biosyn/CONRAD; Oxathiin carboxanilide analogs, Uniroyal/NCI/Southern Research Institute; UC analogs, Uniroyal/NCI/Southern Research Institute

Indication

Disease Entry	ICD 11	Status	REF
Human immunodeficiency virus infection	1C62	Phase 1	[1]

Cross-matching ID

PubChem CID: 3000926
CAS Number: CAS 178870-32-1
TTD Drug ID: DM5XMHB

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Human immunodeficiency virus Reverse transcriptase (HIV RT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[3]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[4]
Zalcitabine	DMH7MUV	Human immunodeficiency virus infection	1C62	Approved	[5]
Tenofovir	DM1IS6U	Chronic hepatitis B virus infection		Approved	[3]
Lamivudine	DMI347A	Chronic HBV infection	1E51.0Z	Approved	[6]
Abacavir	DMMN36E	Human immunodeficiency virus infection	1C62	Approved	[7]
Delavirdine	DM3NF5G	Human immunodeficiency virus infection	1C62	Approved	[6]
Efavirenz	DMC0GSJ	Human immunodeficiency virus infection	1C62	Approved	[6]
Rilpivirine	DMJ0QOW	Human immunodeficiency virus infection	1C62	Approved	[8]
Etravirine	DMGV8QU	Human immunodeficiency virus-1 infection	1C62	Approved	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human immunodeficiency virus Reverse transcriptase (HIV RT)	TT84ETX	POL_HV1B1	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00441909) Phase I Study of Safety and Persistence of UC-781 Vaginal Microbicide. U.S. National Institutes of Health.
2	The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. J Virol. 2005 Sep;79(17):11179-86.
3	Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33.
4	HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.Nat Struct Mol Biol.2012 Jan 22;19(2):253-9.
5	A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. J Biomol Struct Dyn. 1998 Oct;16(2):347-54.
6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7	Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6.
8	Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
9	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.